Overview

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Status:
Completed

Trial end date:
2017-02-13

Target enrollment:

Participant gender:

Summary

This study proposes to determine the safety of the administration of E7820 plus cetuximab and explore the MTD of the combination in a Phase Ib study. In addition, the efficacy of this combination will be explored in patients with colorectal cancer in the Phase II proof of concept phase of the study.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Cetuximab